Hasil Pencarian  ::  Simpan CSV :: Kembali

"Pendahuluan: Hilangnya penjangkaran dan relaps pada perawatan ortodontik menjadi hal yang dapat menyebabkan kegagalan perawatan ortodonti dalam jangka panjang. Pemberian gel emulsi berbahan dasar minyak Zoledronate Bisphosphonate (ZOL) dan campuran Virgin Coconut Oil (VCO) secara topikal memiliki potensi meningkatkan apoptosis osteoklas sehingga dapat dipertimbangkan sebagai alternatif penjangkaran dan pencegahan relaps. Tujuan penelitian ini ialah mengetahui stabilitas fisik dan kadar obat gel emulsi ZOL dengan VCO sebagai syarat suatu sediaan dan pengembangan obat baru pada penyimpanan suhu ruangan (25°C) dan suhu pengiriman (40°C). Metode: Gel emulsi disimpan selama 1 bulan pada suhu 25°C dan 40°C. Parameter pengukuran stabilitas, antara lain pH, viskositas, daya sebar, daya lekat, dan kadar obat. Evaluasi dilakukan pada hari pertama, 7, 14, dan 28. Hasil: Uji repeated measure ANOVA pada penyimpanan suhu 25°C dan 40°C menunjukkan terdapat perbedaan bermakna secara statistik pada parameter pH, viskositas, daya lekat, dan kadar obat antar waktu penyimpanan (p<0,05). Pada parameter kadar obat pada penyimpanan suhu 25°C dan 40°C tidak terdapat perbedaan bermakna antar waktu penyimpanan (p>0,05). Sementara, pada penyimpanan gel emulsi ZOL antara suhu 25°C dan 40°C dengan uji t-test independent menunjukkan bahwa nilai pH pada hari ke-7 dan 14, nilai viskositas pada hari ke-14, nilai daya lekat pada hari ke-7, dan nilai kadar pada hari ke-7 dan 14 berbeda bermakna (p>0.05). Sebaliknya, nilai viskositas pada hari ke-7, daya sebar, dan daya lekat pada hari ke- 14 tidak terdapat perbedaan bermakna secara statistik (p>0.05). Kesimpulan: Gel emulsi zoledronate dengan VCO yang disimpan pada suhu 25°C selama 28 hari relatif stabil. Namun perubahan pada nilai pada uji stabilitas relatif konstan dan dalam batas normal mukosa rongga mulut. Gel emulsi zoledronate yang disimpan pada suhu 40°C selama 28 hari disimpulkan tidak stabil.

---

Introduction: Loss of anchorage and relapse during and after orthodontic treatment could be the leading causes of an unsuccessful result of orthodontic treatment. Various intra and extra oral application have been used to prevent anchorage loss and relapse in orthodontics with some risks and patient dependent compliance. Topical application of gel emulsion Zoledronate Bisphosphonate (ZOL) with Virgin Coconut Oil (VCO) has a potential to increase the apoptosis of osteoclast to prevent undesirable tooth movement. This study aims to analyze and evaluate the physical stability and drug content of gel emulsion zoledronate, VCO, and preservative agent as a new pharmaceutical drug for one month, stored in a room temperature (25°C) and distribution temperature (40°C). The parameters used for evaluation of ZOL gel emulsion are pH value, viscosity, spread ability, adhesive strength, and drug content. Methods: The ingredients of ZOL gel emulsion consisted of ZOL powder, carboxyl methyl cellulose (CMC), VCO, sodium benzoate, antioxidant butylated hydroxytoluene (BHT), and distilled water. The gel emulsions stored for one month at 25°C and 40°C. The parameters used for stability tests were pH, viscosity, spreadability, adhesive strength, and drug content. The ZOL gel emulsion was evaluated on the 1st day, 7th day, 14th day, and 28th day. Results: The result of this study showed that ZOL gel emulsion was clinically stable over 28 days of storage at 25°C. As for the ZOL gel emulsion that stored at 40°C on the 28th day the gel was not stable. Also, there was no significant difference between ZOL gel emulsion at 25°C and 40°C storage. Conclusion: According to the physical stability and drug content test of ZOL gel emulsion, this study concluded that the ZOL gel emulsion stable in the room temperature (25°C) storage. Organoleptic, pH, viscosity, spreadability, adhesive strength value was also stable and the degradation was constant. It is recommended that the storage of ZOL gel emulsion is in room temperature and also well tightly packed."

"Osteogenesis imperfekta (OI) merupakan adalah penyakit genetik kelainan jaringan ikat berupa kerapuhan tulang dan fraktur berulang tanpa adanya trauma yang signifikan. Terdapat berbagai karakteristik klinis yang khas untuk mendiagnosis OI. Terapi bisfosfonat merupakan terapi utama pada OI yang bermanfaat untuk menurunkan insiden patah tulang agar tercapai kualitas hidup yang lebih baik. Penelitian ini bertujuan mengetahui karakteristik klinis dan luaran terapi bisfosfonat pada pasien anak dengan OI di RSCM. Penelitian ini dilakukan secara potong lintang terhadap 71 pasien OI berusia 0-18 tahun di RSCM pada 16-22 November 2020. Data diambil melalui kuesioner daring yang diisi oleh orangtua atau wali. Karakteristik klinis OI mencakup sklera biru (83%) dan patah tulang pada 69 (97%) pasien dengan lokasi paling banyak di tulang femur (66,2%). Hanya terdapat 18 subyek yang sudah melakukan pemeriksaan pendengaran dengan 4 (22%) diantaranya terdapat gangguan pendengaran. Klasifikasi klinis OI paling banyak adalah tipe berat (57%). Enam puluh lima subyek mengalami patahtulang di usia kurang dari 6 tahun termasuk intrauterin dan perinatal. Sebanyak 95,8% subyek mendapatkan terapi bisfosfonat dan hampir seluruhnya diberikan rutin setiap 6 bulan. Terdapat penurunan median kejadian patah tulang sebelum terapi bisfosfonat sebanyak 3,5 kejadian/tahun menjadi satu kejadian/tahun setelah terapi bisfosfonat. Terapi bisfosfonat dapat menurunkan angka kejadian patah tulang setiap tahun.

---

Osteogenesis imperfecta (OI) is a genetic disorder of connective tissue causing bone fragility and fractures in the absence of significant trauma. There are many typical clinical features of OI. Bisphosphonate therapy is the main therapy which significantly decreases fracture rate for better quality of life. This study was aimed to observe the clinical features and outcomes of bisphosphonate therapy in pediatric OI patients. A cross sectional study was conducted at Cipto Mangunkusumo Hospital (CMH) in the period of November 16th-22nd 2020. There were 71 patients aged 0-18 years old included for study analysis. Data were obtained from online questionnaire which was filled by their parents or guardians. The clinical features observed were blue sclera (83%) and fractures which occurred in 69 (97%) patients with the most common location was femur (66.2%). There were only 18 patients who underwent hearing examination and 4 of them (22%) had hearing problem. Most patients had severe OI classification (57%). Sixty-five patients had first fracture when their age <6 years old, including intrauterine and perinatal fractures. A total of 95.8% patients had received bisphosphonate therapy and almost all of patients had received treatment every 6 month. There was a decrease in the number of fractures from 3.5 events/year (before bisphosphonate therapy) to 1 event/year after bisphosphonate therapy. The outcome of bisphosphonate therapy was significant in terms of fracture incidence reduction. Bisphosphonate therapy was able to reduce fracture incidence per year."

"During the early 19th century, it was discovered that adding yellow (now called white) phosphorous to matchstick heads made it easier to ignite matches. The phosphorous vapors were breathed in by workers and combined with other chemicals in the body to produce a potent nitrogen-containing bisphosphonate. Today's oral nitrogen-containing bisphosphonates and intravenous nitrogen-containing bisphosphonates circulate around the body the same way as the phosphorous vapors, and are absorbed into bone and ingested by osteoclasts. When this unique binding process of bisphosphonates to bone occurs, osteoclasts are poisoned, and this reduces or eliminates bone turnover. Alveolar bone in the mandible and maxilla turns over more rapidly than in long bones, so the jaws are a better target for bisphosphonate toxicity. It wasn't until 2003 that today's intravenous and oral nitrogen-containing bisphosphonate medications were implicated as major risk factors in the development of exposed necrotic bone of the jaws. Most of the researchers who reported cases of bisphosphonate-induced osteonecrosis of the jaw found that these patients were treated with zoledronate, pamidronate, or a combination of these drugs, which are commonly used for treating breast cancer or myeloma. In about 5% of cases, subjects with BIONJ were being treated for osteoporosis. Precipitating events that contribute to BIONJ are tooth extractions (about 50% of cases), mandibular exostoses, periodontal disease, and local trauma from ill-fitting dentures. It is not known if the placement of dental implants is a precipitating factor. The book aims to meet the need of medical practitioners working in all fields that use bisphosphonates, and to present the conservative and surgical treatment methods currently in use. There will also be detailed information on the literature relating to dental implants in patients treated with bisphosphonates."

"Bone metastases continue to be a major cause of morbidity in cancer patients, but improved understanding of the biology of bone metastases has led to the identification of drugs that are of potential value in not only their treatment but also their prevention. This book, written by recognized experts in the field, provides a detailed overview of current knowledge on this subject. One important focus of the book is the efficacy of bisphosphonates in preventing bone metastases in patients with breast, lung, and prostate cancer and disease progression in cases of multiple myeloma. The combined use of bisphosphonates and cytostatics is also discussed, with a report on first clinical data. Further topics addressed include the significance of the bone microenvironment, special issues in the elderly patient, the use of bone turnover markers, and initial findings obtained with denosumab."